vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Phillips Edison & Company, Inc. (PECO). Click either name above to swap in a different company.

Phillips Edison & Company, Inc. is the larger business by last-quarter revenue ($190.7M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 7.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.7%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Consolidated Edison, Inc., commonly known as Con Edison or ConEd, is an energy company based in New York City. It is one of the largest investor-owned energy companies in the United States, with approximately $15.26 billion in annual revenues as of 2024, and over $70 billion in assets. The company provides a wide range of energy-related products and services to its customers through its subsidiaries:Consolidated Edison Company of New York, Inc. (CECONY), a regulated utility providing electric...

ESPR vs PECO — Head-to-Head

Bigger by revenue
PECO
PECO
1.1× larger
PECO
$190.7M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+136.8% gap
ESPR
143.7%
7.0%
PECO
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
8.7%
PECO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
PECO
PECO
Revenue
$168.4M
$190.7M
Net Profit
$33.2M
Gross Margin
Operating Margin
50.6%
Net Margin
17.4%
Revenue YoY
143.7%
7.0%
Net Profit YoY
15.1%
EPS (diluted)
$0.32
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
PECO
PECO
Q1 26
$190.7M
Q4 25
$168.4M
$187.9M
Q3 25
$87.3M
$182.7M
Q2 25
$82.4M
$177.8M
Q1 25
$65.0M
$178.3M
Q4 24
$69.1M
$173.0M
Q3 24
$51.6M
$165.5M
Q2 24
$73.8M
$161.5M
Net Profit
ESPR
ESPR
PECO
PECO
Q1 26
$33.2M
Q4 25
$47.5M
Q3 25
$-31.3M
$24.7M
Q2 25
$-12.7M
$12.8M
Q1 25
$-40.5M
$26.3M
Q4 24
$18.1M
Q3 24
$-29.5M
$11.6M
Q2 24
$-61.9M
$15.3M
Operating Margin
ESPR
ESPR
PECO
PECO
Q1 26
Q4 25
50.6%
Q3 25
-11.4%
Q2 25
8.6%
Q1 25
-34.0%
Q4 24
-6.4%
Q3 24
-31.0%
Q2 24
3.5%
Net Margin
ESPR
ESPR
PECO
PECO
Q1 26
17.4%
Q4 25
25.3%
Q3 25
-35.9%
13.5%
Q2 25
-15.4%
7.2%
Q1 25
-62.2%
14.8%
Q4 24
10.5%
Q3 24
-57.2%
7.0%
Q2 24
-83.9%
9.5%
EPS (diluted)
ESPR
ESPR
PECO
PECO
Q1 26
$0.24
Q4 25
$0.32
$0.38
Q3 25
$-0.16
$0.20
Q2 25
$-0.06
$0.10
Q1 25
$-0.21
$0.21
Q4 24
$-0.14
$0.16
Q3 24
$-0.15
$0.09
Q2 24
$-0.33
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
PECO
PECO
Cash + ST InvestmentsLiquidity on hand
$167.9M
$3.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$2.3B
Total Assets
$465.9M
$5.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
PECO
PECO
Q1 26
$3.1M
Q4 25
$167.9M
$3.5M
Q3 25
$92.4M
$4.1M
Q2 25
$86.1M
$5.6M
Q1 25
$114.6M
$5.5M
Q4 24
$144.8M
$4.9M
Q3 24
$144.7M
$6.4M
Q2 24
$189.3M
$7.1M
Total Debt
ESPR
ESPR
PECO
PECO
Q1 26
Q4 25
$2.4B
Q3 25
$2.4B
Q2 25
$2.4B
Q1 25
$2.3B
Q4 24
$2.1B
Q3 24
$2.1B
Q2 24
$2.0B
Stockholders' Equity
ESPR
ESPR
PECO
PECO
Q1 26
$2.3B
Q4 25
$-302.0M
$2.3B
Q3 25
$-451.4M
$2.3B
Q2 25
$-433.5M
$2.3B
Q1 25
$-426.2M
$2.3B
Q4 24
$-388.7M
$2.3B
Q3 24
$-370.2M
$2.2B
Q2 24
$-344.2M
$2.3B
Total Assets
ESPR
ESPR
PECO
PECO
Q1 26
$5.4B
Q4 25
$465.9M
$5.3B
Q3 25
$364.0M
$5.3B
Q2 25
$347.1M
$5.3B
Q1 25
$324.0M
$5.2B
Q4 24
$343.8M
$5.0B
Q3 24
$314.1M
$5.0B
Q2 24
$352.3M
$4.9B
Debt / Equity
ESPR
ESPR
PECO
PECO
Q1 26
Q4 25
1.04×
Q3 25
1.05×
Q2 25
1.04×
Q1 25
0.99×
Q4 24
0.91×
Q3 24
0.94×
Q2 24
0.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
PECO
PECO
Operating Cash FlowLast quarter
$45.2M
$55.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
12.6%
Cash ConversionOCF / Net Profit
1.67×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
PECO
PECO
Q1 26
$55.6M
Q4 25
$45.2M
$348.1M
Q3 25
$-4.3M
$95.4M
Q2 25
$-31.4M
$96.1M
Q1 25
$-22.6M
$60.5M
Q4 24
$-35.0M
$334.7M
Q3 24
$-35.3M
$109.1M
Q2 24
$-7.2M
$78.5M
Free Cash Flow
ESPR
ESPR
PECO
PECO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$-35.5M
Q2 24
$-7.3M
FCF Margin
ESPR
ESPR
PECO
PECO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-68.7%
Q2 24
-9.9%
Capex Intensity
ESPR
ESPR
PECO
PECO
Q1 26
12.6%
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.3%
Q2 24
0.1%
Cash Conversion
ESPR
ESPR
PECO
PECO
Q1 26
1.67×
Q4 25
7.33×
Q3 25
3.87×
Q2 25
7.52×
Q1 25
2.30×
Q4 24
18.45×
Q3 24
9.40×
Q2 24
5.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

PECO
PECO

Rental income$186.3M98%
Fees and management income$3.4M2%

Related Comparisons